TRIPLE NEGATIVE BREAST NEOPLASMS
Clinical trials for TRIPLE NEGATIVE BREAST NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST NEOPLASMS trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug switch strategy aims to outsmart tough breast cancer
Disease control Not yet recruitingThis study tests if switching between two different targeted drugs (sacituzumab govitecan and trastuzumab deruxtecan) can help people with a hard-to-treat, advanced breast cancer called HER2-low triple-negative breast cancer live longer. About 260 adults with metastatic or locall…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New combo therapy aims to fight Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study tests two drug combinations as a first treatment for people with advanced triple-negative breast cancer that has spread and is PD-L1 positive. About 150 participants will receive either sacituzumab govitecan plus toripalimab or toripalimab plus nab-paclitaxel. The goal…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated May 04, 2026 16:23 UTC